If you've come across ACE-031 in the context of muscle wasting research or bodybuilding communities, you've probably noticed how fast the conversation gets technical. ACE-031, also known as Ramatercept, is an investigational recombinant fusion protein studied for its ability to promote muscle growth by binding to myostatin and other proteins that naturally restrict muscle development. At PeptideValidation.com, we compile peer-reviewed reference data so researchers and science-minded readers get accurate context, not speculation.

What Is ACE-031? A Plain-Language Definition

ACE-031 (Ramatercept) is a soluble ActRIIA-Fc fusion protein that acts as a ligand trap for myostatin (GDF-8), GDF-11, and activin A, three proteins that suppress skeletal muscle growth. By sequestering these ligands before they can bind muscle-cell receptors, ACE-031 removes a natural brake on muscle hypertrophy. Its serum half-life in humans is approximately 10 to 14 days.

ACE-031 pairs the extracellular domain of activin receptor type IIA (ActRIIA) with a human IgG1 Fc region. The result is a circulating decoy receptor that intercepts inhibitory ligands before they reach membrane-bound ActRIIA on skeletal muscle cells.

The three primary ligands it traps are myostatin (GDF-8), GDF-11, and activin A. All three are negative regulators of muscle mass. Remove their signaling, and the biological brakes on hypertrophy are partially released.

The IgG1 Fc domain does more than provide structural stability. It confers FcRn-mediated recycling, which extends the serum half-life to roughly 10 to 14 days in human pharmacokinetic studies. That long half-life is one reason dosing intervals in clinical trials were measured in weeks, not days.

Acceleron Pharma (now part of Merck) developed ACE-031 and carried it into Phase 2 clinical trials between 2010 and 2013. The molecular weight of the dimeric form is approximately 100 kDa, and recombinant production uses CHO (Chinese hamster ovary) cell lines. Reference-grade material is characterized by SDS-PAGE, SEC-HPLC, and ELISA-based binding assays.

ACE-031 Dosage Protocols in Published Research

Phase 2 DMD trials used subcutaneous ACE-031 doses ranging from 0.1 mg/kg to 3.0 mg/kg, administered every 4 weeks. The 1 mg/kg dose produced measurable lean mass gains at 12 weeks with a tolerable safety profile in pediatric patients.

Published literature is the only credible source for ACE-031 dosage data. The Phase 2 trial in boys with Duchenne muscular dystrophy (DMD) tested subcutaneous doses from 0.1 mg/kg up to 3.0 mg/kg, given every 4 weeks over a 12-week treatment window.

At 1 mg/kg, researchers documented statistically significant increases in lean body mass measured by DEXA scan. Higher doses did not consistently produce proportionally larger lean mass gains, and the adverse event profile became more pronounced above 1 mg/kg.

For researchers cross-referencing an ACE-031 dosage protocol, these are the anchors: 1 mg/kg subcutaneous, every 28 days, 3 doses over 12 weeks. Intravenous administration was also explored in preclinical and early-phase work, though the subcutaneous route dominated Phase 2 enrollment.

The ACE-031 1 mg/kg benefits documented in trial reports include roughly 3 to 5 percent increases in total lean mass from baseline over 12 weeks in a pediatric population. Extrapolating these numbers to adult or athletic populations is not scientifically valid without direct study data, a point worth stating plainly.

Any discussion of ACE-031 peptide dosage in bodybuilding forums tends to reference these clinical figures as a starting point, even though the compound has never been approved for any indication and is not commercially available as a therapeutic product.

ACE-031 Results in Bodybuilding Contexts: What the Data Actually Shows

Clinical Phase 2 results showed ACE-031 increased lean body mass by approximately 3 to 5 percent over 12 weeks in pediatric DMD patients. No controlled human data exists for ACE-031 results in bodybuilding or healthy adult populations.

The ACE-031 results bodybuilding communities reference almost always trace back to the same two Phase 2 trial publications. The trial population was boys aged 6 to 15 with DMD, not healthy adult athletes. That distinction is not a technicality. The baseline muscle physiology, disease state, and hormonal environment in a DMD patient are fundamentally different from a trained adult.

That said, the mechanistic argument is clear enough to see why the compound attracts interest. Blocking myostatin, GDF-11, and activin A simultaneously creates a broader anabolic signal than targeting any single ligand alone. Myostatin inhibition in animal models consistently produces significant muscle hypertrophy. The mdx mouse model, a common DMD proxy, shows dramatic morphological changes when myostatin signaling is disrupted.

What the human data cannot confirm is whether those animal-model effect sizes translate to eugonadal adults with intact muscle physiology. A 2013 review in the Journal of Clinical Investigation noted that myostatin's role in healthy adult humans may be more context-dependent than rodent studies suggest.

For an ACE-031 cycle discussion to have scientific grounding, you'd need controlled data in adult subjects. That data does not currently exist in peer-reviewed literature. PeptideValidation.com flags this gap explicitly in our reference materials, because overstating what the evidence shows is a research quality problem, not just an editorial one.

ACE-031 Side Effects: The Clinical Record

The Phase 2 DMD trial was paused in 2013 primarily due to vascular adverse events: nosebleeds (epistaxis) and telangiectasia (small dilated blood vessels visible on skin). These effects were attributed to broader ActRIIA pathway inhibition beyond skeletal muscle, affecting vascular endothelial signaling.

ACE-031 side effects documented in the Phase 2 program fall into two main categories: vascular and musculoskeletal.

On the vascular side, nosebleeds and telangiectasia appeared at a frequency that prompted Acceleron to pause the program. The proposed mechanism is that ActRIIA ligands, particularly activin A, play a regulatory role in vascular endothelial homeostasis. A broad ligand trap like ACE-031 disrupts that signaling alongside the desired muscle effects.

On the musculoskeletal side, there were signals around gum bleeding and changes in bone mineral density. The DEXA-based bone endpoints in the trial actually showed increases in bone mineral density alongside lean mass gains, which was considered a potentially favorable secondary finding. But the vascular safety signal outweighed the positive bone data in the risk-benefit calculus.

For researchers designing next-generation myostatin inhibitors, the ACE-031 adverse event profile is an important lesson in pathway specificity. Ligand-trap designs with broader coverage trade selectivity for potency, and the vascular biology of the ActRIIA pathway makes that tradeoff consequential.

The off-target exposure point is directly relevant when comparing ACE-031 to antibody-based approaches like bimagrumab, which targets the receptor rather than circulating ligands. Receptor-targeting narrows the inhibition profile, though it also limits the ceiling on ligand sequestration. PeptideValidation.com's reference data includes side-by-side pharmacology summaries for both approaches.

ACE-031 vs Follistatin 344: Key Mechanistic Differences

ACE-031 inhibits myostatin by acting as a soluble decoy receptor that traps multiple TGF-beta family ligands. Follistatin 344 also binds and neutralizes myostatin, but it does so through direct protein-protein interaction and additionally inhibits activin, BMP, and other ligands via a different binding mechanism and with a much shorter half-life.

The ACE-031 vs follistatin 344 comparison comes up often in research and discussion forums, and the two compounds are related but meaningfully different.

Follistatin 344 is a naturally occurring splice variant of the follistatin protein. It binds myostatin and activin through direct protein-protein contacts, neutralizing them before they can engage receptors. Its half-life is short, measured in hours rather than days, and it does not carry an Fc domain for recycling.

ACE-031 is a purpose-engineered fusion protein. The ActRIIA extracellular domain gives it structural similarity to the native receptor, so ligands bind with high affinity. The Fc tail extends its half-life to approximately 10 to 14 days. That pharmacokinetic difference alone separates their dosing profiles substantially.

In terms of ligand coverage, there is meaningful overlap. Both neutralize myostatin and activin A. Follistatin 344 also inhibits BMPs (bone morphogenetic proteins) via its FS domain, which ACE-031 does not target through its ActRIIA mechanism. ACE-031 additionally captures GDF-11 with high affinity, while follistatin's affinity for GDF-11 is moderate.

Neither compound has regulatory approval. Neither has been studied in healthy adult humans in a controlled clinical trial published in a peer-reviewed journal. Researchers reviewing ACE-031 dosage alongside follistatin 344 protocols should weight clinical-trial data over forum-derived anecdote, every time.

For a more thorough breakdown of ACE-031's mechanism relative to the broader class of myostatin inhibitors, the full reference guide covers the pharmacology in detail.

Structural and Pharmacokinetic Reference Data

ACE-031 key reference specifications: molecular weight approximately 100 kDa (dimer), produced in CHO cells, subcutaneous bioavailability documented in Phase 2, serum half-life 10 to 14 days in humans, primary ligands targeted: myostatin (GDF-8), GDF-11, activin A.

Researchers pulling ACE-031 specifications for literature comparison need a consistent set of reference values. Here are the parameters documented across peer-reviewed sources and manufacturer characterization data:

• Molecular weight: approximately 100 kDa in dimeric form; monomer approximately 50 kDa before Fc-mediated dimerization
• Expression system: CHO (Chinese hamster ovary) cells
• Characterization methods: SDS-PAGE (reduced and non-reduced), SEC-HPLC for aggregate detection, ELISA for ActRIIA-ligand binding confirmation
• Isoelectric point: in the range reported for IgG1 Fc fusion proteins, typically pH 6 to 8 depending on glycosylation
• Serum half-life: approximately 10 to 14 days in human subjects (Phase 2 pharmacokinetic data)
• Route of administration studied: subcutaneous (primary in Phase 2), intravenous (preclinical and Phase 1 exploration)
• Primary endpoints tracked: lean body mass and bone mineral density by DEXA, motor function assessment

PeptideValidation.com compiles these parameters alongside their primary source citations, so a researcher does not have to cross-reference ClinicalTrials.gov, primary trial publications, and manufacturer spec sheets separately. Every data point links back to a citable source.

One specification worth flagging: purity thresholds used in published studies typically specify greater than 95 percent purity by SEC-HPLC and less than 1 EU/mg endotoxin. These benchmarks matter when evaluating any recombinant material against published reference standards.

What Researchers Should Know Before Using ACE-031 Reference Data

ACE-031 has not received regulatory approval from the FDA or EMA. Its clinical development was paused in 2013 due to vascular adverse events. All published data comes from pediatric DMD trials. Extrapolating these findings to healthy adults or athletic populations is not supported by current evidence.

Context is everything when working with ACE-031 reference data. Here are the key caveats that should accompany any research use:

First, the compound has no approved indication. The Phase 2 program was paused, not completed, and no regulatory submission has been made as of 2026. Any material described as ACE-031 available outside a licensed research context cannot be verified against the clinical-grade specification.

Second, all human pharmacokinetic and efficacy data comes from a pediatric patient population with a specific neuromuscular disease. The lean mass gains observed in 6- to 15-year-old DMD patients cannot be directly mapped to an ACE-031 cycle in a healthy adult without separate controlled data.

Third, the adverse event profile, particularly the vascular effects, was serious enough to halt a program that had demonstrated efficacy. That is a meaningful data point, not a footnote.

For researchers working on next-generation myostatin inhibition strategies, ACE-031's clinical history remains one of the most informative datasets available precisely because it went far enough to surface real-world toxicity signals. Understanding why the program paused is at least as valuable as understanding why it showed efficacy.

PeptideValidation.com's reference materials for ACE-031 are built around this standard: accurate data, traceable citations, and honest representation of what the evidence does and does not support. That commitment is what makes the resource useful for serious research rather than speculation.

Frequently asked questions